

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

e Application of:
Thomas Kodadek

Serial No.: 10/754,457

Filed: January 9, 2004

For: METHODS AND COMPOSITIONS COMPRISING CAPTURE AGENTS

Group Art Unit: 1645

Examiner: Unknown

Atty. Dkt. No.: UTSD:935US

#### CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to:, MS AMENDMENT, Commissioner for Patents, P. C. Box 1450, Alexandria, VA 22313-1450, photoe date below:

June 30, 2004

Date

Steven L. Highlander

### INFORMATION DISCLOSURE STATEMENT

### MS AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as

defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first

Official Action reflecting an examination on the merits, and hence is believed to be timely filed

in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the

filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R.

§§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the

Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit

Account No.: 50-1212/UTSD:935US.

Applicant respectfully requests that the listed documents be made of record in the present

case.

Respectfully submitted,

Steven L. Highlander

Attorney for Applicant

Reg. No. 37,642

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 474-5201

Date:

June 30, 2004





# FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

STEVEN L. HIGHLANDER
PARTNER
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: TELEPHONE: (512) 536-3184 (512) 474-5201

FACSIMILE:

(512) 536-4598

June 30, 2004

CERTIFICATE OF MAILING 37 C.F.R 1.8

I certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or the date below:

June 30, 2004

Date

Stever L. Highlander

MS AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

RE:

U.S. Patent Application No. 10/754,457 entitled "METHODS AND COMPOSITIONS

COMPRISING CAPTURE AGENTS" - Thomas Kodadek

Our reference: UTSD:935US

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references A1-A13, B1-B9 and C1-C27.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSD:935US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Steven L. Highlander Reg. No. 37,642

SLH/kmv

Encl.: as noted

ied)

Atty. Docket No. UTSD:935US

Serial No. 10/754,457

List of Patents and Publications for Applicant's

Applicant

Information Disclosure Statement

Thomas Kodadek

(Use several sheets if necessary)

Filing Date: January 9, 2004

Group: 1645

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art See Page 2

## **U.S. Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	2002/0006620	1/17/02	Short	435	6	4/03/01
	A2	2002/0022227	2/21/02	Short	435	6	4/12/01
	A3	2002/0098493	7/25/02	Nathan	435	6	5/25/01
	A4	2002/0137106	9/26/02	Leung and Lomas	435	7.9	3/07/02
	A5	4,789,628	12/06/88	Nayak	435	7	6/16/86
	A6	5,149,626	9/22/92	Fleming	435	7.9	12/18/89
	A7	6,297,059	10/02/01	Song and Swanson	436	501	6/22/99
	A8	6,306,643	10/23/01	Galtalen and Chee	435	287.2	8/24/98
	A9	6,344,330	2/05/02	Ellman and Choong	435	7.1	3/27/98
	A10	6,344,334	2/05/02	Ellman and Choong	435	7.1	3/26/99
	A11	6,365,418	4/02/02	Wagner et al.	436	518	5/18/00
	A12	6,406,921	6/18/02	Wagner et al.	436	518	7/14/98
	A13	6,465,183	10/15/02	Wolber	435	6	7/01/99

# **Foreign Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
ô	B1	0268296	5/25/88	Europe			English
,	B2	0317804	5/31/89	Europe			English
5	В3	0491362	6/24/92	Europe			Abstract
1	B4	0586618	7/16/97	Europe			English
7	B5	0818467	1/14/98	Europe			English
A	В6	WO 01/69258	9/20/01	PCT			English
	В7	WO 02/31510	4/18/02	PCT			English

25391809.1

**EXAMINER:** 

**DATE CONSIDERED:** 

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

			· · · · · · · · · · · · · · · · ·				8
` ,			Atty. Docket N UTSD:935US	lo.	Serial 10/754		
List of Patents and Publications for Applicant's			Applicant Thomas Koda				
요! .	ORMATIO	N DISCLOSURE ST	<b>FATEMENT</b>			- 1 -	
U.S	(Use se	everal sheets if necessar	ry)	Filing Date: January 9, 200	14	Group 1645	p:
U.:	S. Patent	Documents	Foreig	n Patent Document			Other Art
	See P	age 1		See Page 1		S	ee Page 2
		F	oreign F	Patent Docum	nents	1,-1.	
Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translatior Yes/No
9	В8	WO 02/063299	8/15/02	PCT			English
	В9	WO 03/074990	9/12/03	PCT			English
(	Other A	Art (Includin	g Autho	or, Title, Date	Pertin	ent Pag	ges, Etc.)
Exam. Init.	Ref. Des.	-		Citatio	n		7 117 21
	C1 /			ek, "Mixed-element of- affinity protein capt			
C2 Burkoth et al., "Toward the synthesis of artificial proteins: the discovery of an an helical peptoid assembly," Chem. Biol., 9:647-654, 2002.  C3 Cussac et al., "A Sos-derived peptidimer blocks the Ras signaling pathway by bir Grb2 SH3 domains and displays antiproliferative activity," FASEB J., 13:31-38,				of an amphiphilic			
	C4 Fancy and Kodadek, "Chemistry efficient cross-linking triggered by 96:6020-6024, 1999.						
	C5 /	Figliozzi <i>et al.</i> , "S 267:437-447, 199	Synthesis of 1 6.	N-substituted glycine	peptoid lib	oraries,"Met	hods Enzymol.,
	C6 -	Hajkuk <i>et al.</i> , "Di 1997.	scovering his	gh-affinity ligands fo	r proteins,"	Science, 2	78(5337):497-499,
C7 Han and Kodadek, "Peptides sele activation domains in yeast," J. E. Kiessling et al., "Synthetic multi Curr. Opin. Chem. Biol., 4:696-7							
				ne explorati	on of cell-s	urface interactions	
C9 Kirshenbaum et al., "Sequence-specific polypeptoids: a diverse family of he stable secondary structure," Proc. Natl. Acad. Sci., USA, 95:4303-4308, 199							
	C10	Kitov et al., "Shig Nature, 403:669-6		are neutralized by ta	ilored mult	tavalent car	bohydrate ligands,
25391809.1	l 						
						_	

CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

				8	
Form PTO-1449 (modified)			Atty. Docket No.	Serial No.	
	•		UTSD:935US	10/754,457	
	of Patents and Publications fo	r Applicant's	Applicant		
11			Thomas Kodadek		
INFORMATION DISCLOSURE STATEMENT					
10 S				Group:	
(Use several sneets if necessary)		ary)	January 9, 2004	1645	
DEFIG	U.S. Patent Documents	Foreign	Patent Documents	Other Art	
	See Page 1		See Page 1	See Page 2	

(	Other Art (Including Author, Title, Date Pertinent Pages, Etc.)					
Exam. Init.	Ref. Des.	Citation				
	C11/	Kodadek, "Protein microarrays: prospects and problems," Chem. Biol., 8:105-115, 2001.				
	C12 /	Kodadek, "Development of protein-detecting microarrays and related devices," <i>Trends Biochem. Sci.</i> , 27(6):295-300, 2002.				
	C13 /	Koehler et al., "Discovery of an inhibitor of a transcription factor using small molecule microarrays and diversity-oriented synthesis," J. Amer. Chem. Soc., 125:8420-8421, 2003.				
	C14	- Kuruvilla et al., "Dissecting glucose signaling with diversity-oriented synthesis and small-molecule microarrays," <i>Nature</i> , 416:653-657, 2002.				
	C15	-Ladbury et al., "Measurement of the binding of tyrosyl phosphopeptides to SH2 domains: a reappraisal.," Proc. Natl. Acad. Sci., USA, 92:3199-3203, 1995.				
	C16	Maly et al., "Combinatorial target-guided ligand assembly: identification of potent subtype-selective c-Src inhibitors," Proc. Natl. Acad. Sci., USA, 97:2419-2424, 2000.				
	C17	Melcher and Xu, EMBO J., "Gal80-Gal80 interaction on adjacent Gal4p binding sites is required for complete GAL gene repression," 20:841-851, 2001.				
	C18	Merritt et al., "Characterization and crystal structure of a high-affinity pentavalent receptor-binding inhibitor for cholera toxin and E. coli heat-labile enterotoxin," J. Amer. Chem. Soc., 124:8818-8824, 2002.				
	C19 -	Olejniczak et al., "Stromelysin inhibitors designed from weakly bound fragments: effects of linking and cooperativity," J. Amer. Chem. Soc., 119:5828-5832, 1997.				
	C20 _	Oliver et al., "Multiplexed Analysis of Human Cytokines by Use of the FlowMetrix System," Clinical Chemistry, 44:2057-2060, 1998.				
	C21./	Schreiber, "Target-oriented and diversity-oriented organic synthesis in drug discovery," <i>Science</i> , 287(5460), 1964-1969, 2000.				
	C22.	Shuker et al., "Discovering high-affinity ligands for proteins: SAR by NMR," Science, 274:1531-1534, 1996.				
	C23 /	Stoll et al., "Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53," Biochemistry, 40:336-344, 2001.				
	C24 Z	Terskikh et al., "'Peptabody': a new type of high avidity binding protein," Proc. Natl. Acad. Sci., USA, 94:1663-1668, 1997.				

25391809.1

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

For	m PTO-1449 (modified)	<u>-</u>	Atty. Docket No.	Serial No.	
			UTSD:935US	10/754,457	
List	of Patents and Publications for	r Applicant's	Applicant		_
			Thomas Kodadek		
oh	INFORMATION DISCLOSURE S	STATEMENT			
اي			Filing Date:	Group:	
(Use several sheets if necessary)		January 9, 2004	1645		
			Patent Documents	Other Art	
reight	See Page 1		See Page 1	See Page 2	

# Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C25 /	Thoma et al., "Nanomolar E-selectin inhibitors: 700-fold potentiation of affinity by multivalent ligand presentation," J. Amer. Chem. Soc., 123:10113-10114, 2001.
	C26 ?	Vignali, "Multiplexed particle-based flow cytometric assays," J. of Immunol. Methods, 243:243-255, 2000.
	C27	Woodbury and Vinton, "Methods of screening combinatorial libraries using immobilized or restrained receptors," J. Chromatogr B Biomed. Sci. Appl., 725:113-137, 1999.

25391809.1

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.